Lymphoma
Dana Farber: 14-174: Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome
Leukemia
A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI - 1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) [...]
Gastrointestinal System
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) EA2142: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic [...]
Symptom Management and Cancer Control Protocols
EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EAQ162CD: Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent S0820: Phase III Double Blind Placebo-Controlled Trial of Eflomithine & Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer
Genitourinary System
A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors – MALE GENDER ONLY. NRG GU006: Phase II, Double Blinded, Placebo Controlled Randomized Trial of [...]
Breast
A011106: Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study A011502: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The Aspirin for Breast Cancer Study (ABC Study) A171601: A Phase II Trial [...]
Myeloma
A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy (Presently in Phase II)
Lung
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) C30610: Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving [...]
Gynecologic
EAY131 (MATCH): Molecular Analysis for Therapy Choice GOG 0238: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus GOG 0263: Randomized phase III clinical trial of adjuvant radiation vs. chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy [...]
Medical Oncology & Infusion Services Transitioning to Partner Hospitals
You may have recently heard news regarding changes planned for West Michigan Cancer Center & Institute for Blood Disorders (WMCC). With this article, we hope to clarify the news and explain what patients and caregivers can anticipate moving forward. Our partner hospitals—Borgess and Bronson—have created a plan to strengthen the delivery of cancer care in [...]